Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
Ilya Pharma AB
Ilya Pharma AB
Activities:
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Overcoming CMC challenges in cell and gene therapy: part II
Certara’s Dr Hien Anh Bruno, Associate Director, Chemistry, Manufacturing and Controls (CMC), and Dr Deven Shah, CMC Lead, propose mitigation strategies to address the CMC...
SNIPR Biome receives funding to progress CRISPR medicine SNIPR001 into clinical trials
Phase 1b/2a trial will evaluate SNIPR001 for the prevention of E.coli infections in patients undergoing hematopoietic stem cell transplantation
Kindeva Drug Delivery appoints Denis Johnson as Chief Operating Officer
Denis will be responsible for optimising global operations for the company
SeaBeLife awarded over €1.5 million in i-Nov innovation competition
Funding for company’s SeaBeEYE project will be used to develop a new therapeutic approach for geographic atrophy, a form of age-related macular degeneration
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Ingredients
Ilya Pharma strengthens supply chain with strategic investment
The immunotherapy expert has acquired Nordic Bioanalysis located at the previous AstraZeneca site in south of Stockholm
Finance
Ilya Pharma strengthens senior management
Pfizer veteran Sylvia McBrinn joins Board while Oskar Lund becomes CFO
Patient Experience
Ilya Pharma awarded engineered lactic acid bacterial strain patent
The patent covers the use of engineered lactic acid bacterial strains for all human and animal wounds, not just skin
Regulatory
Ilya Pharma takes minibioreactor wound care biologic into the clinic
Swedish MPA approves first-in-human trial of Ilya Pharma’s first-in-class ILP100 topical wound care therapy
Pharmaceutical
Treating chronic wounds with live biotherapeutics
Angharad Baldwin talks to Evelina Vågesjö, CEO, and Peter Frank, Drug Development Manager, of Swedish biologics company, Ilya Pharma, about using live bacteria to treat chronic wounds
Subscribe now